Pfizer Inc.PFE announced that the FDA has served a complete response letter (CRL) on its supplemental new drug application (sNDA) for oral Xeljanz for the treatment of adults suffering from moderate to severe chronic plaque psoriasis. In the CRL,
Pfizer's Oral Formulation of Xeljanz Gets CRL from the FDA
